These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38951433)

  • 1. The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.
    Guchelaar NAD; Buck SAJ; van Doorn L; Hussaarts KGAM; Sandberg Y; van der Padt-Pruijsten A; van Alphen RJ; Poppe-Manenschijn L; Vleut I; de Bruijn P; van Leeuwen RWF; Mostert B; Eskens FALM; Oomen-de Hoop E; Koolen SLW; Mathijssen RHJ
    Clin Pharmacokinet; 2024 Jul; 63(7):1037-1044. PubMed ID: 38951433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
    Müller F; Weitz D; Mertsch K; König J; Fromm MF
    Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
    Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
    Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
    Chevalier C; Perrimond-Dauchy S; Dubourg J; Fouqueray P; Bolze S
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):725-733. PubMed ID: 32860624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
    Xiao G; Rowbottom C; Boiselle C; Gan LS
    Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
    Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
    Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
    J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
    Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
    Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
    Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
    Choi T; Komirenko AS; Riddle V; Kim A; Dhuria SV
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):818-826. PubMed ID: 30605260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
    Müller F; Weitz D; Derdau V; Sandvoss M; Mertsch K; König J; Fromm MF
    Mol Pharm; 2017 Sep; 14(9):2991-2998. PubMed ID: 28708400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
    Cho SK; Chung JY
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
    Wang ZJ; Yin OQ; Tomlinson B; Chow MS
    Pharmacogenet Genomics; 2008 Jul; 18(7):637-45. PubMed ID: 18551044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
    Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
    Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.